AnaptysBio (ANAB) News
NASDAQ: ANABHealth CareBiotechnology: Pharmaceutical PreparationsUSD
46.63-0.77 (-1.62%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ANAB news summary
We found 12 recent headlines mentioning AnaptysBio (ANAB): 1 in the past week and 6 in the past 30 days, most often from Nasdaq, Seeking Alpha, GlobeNewswire. For price context, ANAB is down 1.62% at $46.63. The most recent story, "3 Stocks With Superb Earnings Acceleration to Buy Before 2027", was published by Nasdaq on Nov 19, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest AnaptysBio headlines
- 3 Stocks With Superb Earnings Acceleration to Buy Before 2027AnaptysBio, Ensign Group and CEVA emerge as top earnings acceleration picks, with projected annual earnings growth of up to 913%.NasdaqCEVA, ENSG, ANAB
- AnaptysBio, Inc. Reports Collaboration Revenue of $30.3 million for the Three Months Ended September 30, 2026AnaptysBio, Inc. reported collaboration revenue of $30.3 million for the three months ended September 30, 2026, compared to $76.3 million for the three months ended September 30, 2025. The decrease…Nasdaq
- AnaptysBio GAAP EPS of $0.11 misses by $0.28, revenue of $30.27M misses by $3.19MSeeking Alpha
- Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business UpdateSAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza…GlobeNewswire
- Anaptys Announces Participation in Upcoming Investor ConferencesSAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza…GlobeNewswire
- AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.NasdaqANAB, BMY
- AnaptysBio quickly drops amid hearing on GSK/Tesaro contract breachSeeking Alpha
- CytoDyn Appoints Robert E. Hoffman As CEO; Lalezari To Focus On Research(RTTNews) - CytoDyn Inc. (CYDY), a clinical-stage biotechnology company developing leronlimab for oncology indications, announced the appointment of Robert E. Hoffman as Chief Executive Officer…NasdaqANAB, HRTX, SUN
- GSK's Jemperli Becomes First Approved Immunotherapy For MSI-H/dMMR Locally Advanced Renal Cancer(RTTNews) - GSK plc (GSK) announced that the U.S. FDA has approved Jemperli as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H) or mismatch…NasdaqANAB, GSK, BRK.A
- Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal CancerSAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza…GlobeNewswire
- AnaptysBio gains as GSK granted FDA label expansion for JemperliSeeking Alpha
- Why This IPO Stock, An AnaptysBio Spinoff, Just Skyrocketed More Than 25%First Tracks Biotherapeutics posted "impressive" results for its celiac disease treatment Monday, and the IPO stock surged by double digits. The post Why This IPO Stock, An AnaptysBio Spinoff, Just…Investor's Business Daily